The MERITTM Programme has been developed and funded by Novo Nordisk.
MERIT™ (Meeting Educational Requirements Improving Treatment) is a two-part flexible education programme developed by Novo Nordisk. MERIT™ is a competency-based programme and is for all healthcare professionals involved in diabetes care. The programme combines the theory required to support diabetes management followed by the provision of tailored clinical support from specialist diabetes teams.
This module covers all aspects surrounding GLP1 RA therapy and, where it is appropriate, enabling healthcare professionals to feel confident to consider GLP1 RA therapy treatment for their patients.
This training is delivered via MS Teams.
Upon booking, your email address will be provided to Novo Nordisk.